Alembic Pharmaceuticals Ltd.

APLLTD

₹1216.35

1.28% (15.4)

Market Cap

₹23,934 Cr.

P/E

38.86

About

Alembic Pharmaceuticals Limited, a flagship company of the Alembic Group, is engaged in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients. W… Read more

Alembic Pharmaceuticals Limited, a flagship company of the Alembic Group, is engaged in manufa… Read more

Low

707

52W Range

High

1225

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Forensics

10 Yes

Positive for this company

1 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE

Latest

12.78%

3yr Average

10.18%

5yr Average

15.78%

Net Profit Margin

Latest

9.89%

3yr Average

8.59%

5yr Average

13.0%

ROCE

Latest

14.29%

3yr Average

11.98%

5yr Average

17.34%

Debt to Equity

Latest

0.09

3yr Average

0.12

5yr Average

0.2

Market Share

1.40 %

(as of Jun 23)

Historic

Anti - Diabetes - Market Share

2.10 %

(as of Jun 23)

Historic

Anti-Infectives - Market Share

0.14 %

(as of Nov 21)

Historic

Anti-Malarial - Market Share

0.01 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.26 %

(as of Nov 21)

Historic

Blood Related - Market Share

1.80 %

(as of Jun 23)

Historic

Cardiovascular - Market Share

4.20 %

(as of Jun 23)

Source/Historic

Cold & Cough Medication Market Share

0.20 %

(as of Jun 23)

Source/Historic

Dermatology - Market Share

0.02 %

(as of Nov 21)

Historic

Endocrinology - Market Share

1.20 %

(as of Jun 23)

Historic

Gastro-Intestinal - Market Share

3.10 %

(as of Jun 23)

Source/Historic

Gynecology - Market Share

0.10 %

(as of Nov 21)

Historic

Neurological - Market Share

2 %

(as of Jun 23)

Source/Historic

Ophthalmology - Market Share

0.83 %

(as of Nov 21)

Historic

Pain - Market Share

1.50 %

(as of Jun 23)

Historic

Pharmaceutical Sector - Market Share

1.85 %

(as of Nov 21)

Historic

Respiratory - Market Share

3.67 %

(as of Nov 21)

Historic

Urology - Market Share

0.80 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up - Domestic Branded Formulation Business

Product Wise Break-Up

Product Wise Break-Up - Formulations

Location Wise Break-Up - API

Location Wise Break-Up - Formulations

Location Wise Break-Up

Therapeutic Area Break-Up

Acute vs Chronic - Formulations

Operational Metrics

US DMF Filings (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Number of ANDA's Filed in Latam
Source
Number of ANDA's Approved by Latam
Source
Number of ANDA's Filed in South Africa
Source
Number of ANDA's Approved by South Africa
Source
Number of ANDA's Filed in Australia
Source
Number of ANDA's Approved by Australia
Source
Number of ANDA's Filed in Canada
Source
Number of ANDA's Approved by Canada
Source
Number of ANDA's Filed in Europe
Source
Number of ANDA's Approved in Europe
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Azithral

Tellzy

Zeet

Suppliers

Aarti Drugs Ltd.
Shaily Engineering Plastics Ltd.
ICE Make Refrigeration Ltd.
Bharat Parenterals Ltd.
Take Solutions Ltd.
Hindusthan National Glass & Industries Ltd.
Jocil Ltd.

Showing 5 of 7

FAQs on Alembic Pharmaceuticals Ltd. Business

What does Alembic Pharma do?

Alembic Pharmaceuticals Limited is a top pharmaceutical company in India known for its expertise in India Formulations, International Generics, and Active Pharmaceutical Ingredients. It excels in oncology, injectables, and ophthalmology.

Who are the competitors of Alembic Pharma?

Alembic Pharma major competitors are Natco Pharma, Pfizer, JB Chem & Pharma, Astrazeneca Pharma I, Ajanta Pharma, Sanofi India, Ipca Laboratories.
Market Cap of Alembic Pharma is ₹23,934 Crs.
While the median market cap of its peers are ₹23,973 Crs.

Is Alembic Pharma financially stable compared to its peers?

Alembic Pharma seems to be less financially stable compared to its peers.
Altman Z score of Alembic Pharma is 12.1 and is ranked 6 out of its 8 competitors.

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Jun			Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec